Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis.
Journal: mAbs
Published: April 15, 2026
The immunogenic potential of AZD1402 (Elarekibep) T-cell epitopes in healthy volunteers and drug-exposed clinical trial participants.
Journal: Archives of toxicology
Published: January 20, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA).
Journal: Respiratory research
Published: October 24, 2025
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma.
Journal: British journal of clinical pharmacology
Published: April 01, 2025
Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.
Journal: British journal of clinical pharmacology
Published: December 06, 2019
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
Journal: International journal of rheumatic diseases
Published: March 26, 2018
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 03, 2017
Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: April 13, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 05, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: September 30, 2016
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Journal: Arthritis research & therapy
Published: April 10, 2013
Last Updated: 09/26/2026